← Eichor
Condition: Oligo Metastatic Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Oligo Metastatic Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma
Phase 2 · 1 location(s) · Yale University · NCT07048457COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the
Phase 2 · 7 location(s) · The Netherlands Cancer Institute · NCT05301881Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC
Phase 2 · 1 location(s) · Tata Memorial Hospital · NCT05277844Metastasis-directed Therapy for Oligometastases of Breast Cancer
Phase 3 · 1 location(s) · Tokyo Medical and Dental University · NCT06135714Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Mela
Phase 3 · 15 location(s) · ETOP IBCSG Partners Foundation · NCT05522660Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer
Phase 2 · 1 location(s) · Centre hospitalier de l'Université de Montréal (CHUM) · NCT04989725Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer
Phase 1/Phase 2 · 2 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT06439888Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
Phase 3 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06523673Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.
Phase N/A · 1 location(s) · Tata Memorial Hospital · NCT07400809Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oli
Phase 3 · 2 location(s) · Ming-Yuan Chen · NCT07481799SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases
Phase 2 · 1 location(s) · AHS Cancer Control Alberta · NCT05775146MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)
NA · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05183074Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Ch
Phase 1 · 1 location(s) · Mayo Clinic · NCT06058663Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatmen
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT07210086Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/
NA · 14 location(s) · Robert Olson · NCT05784428Basket Study for Oligo-metastatic Breast Cancer
Phase 2 · 1 location(s) · The Netherlands Cancer Institute · NCT05982678BOne Metastases REgistry for Patients Undergoing cryoAbLation With curatIve purpoSe
Phase N/A · 5 location(s) · Cardiovascular and Interventional Radiological Society of Eu · NCT06480955Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-rec
Phase 2 · 3 location(s) · Ontario Clinical Oncology Group (OCOG) · NCT06654336Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
Phase 2 · 1 location(s) · University of Oklahoma · NCT07223541Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer
NA · 7 location(s) · Karin Soderkvist · NCT04983095
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.